Home › Companies › ZENTALIS PHARMACEUTICALS INC. › 2024-2025

ZENTALIS PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and ZENTALIS PHARMACEUTICALS INC.’s Form 8-K, filed 2025-06-18 (Item 5.07 on EDGAR). Page generated 02 October 2026.

5Ballot items
126Asset managers
731Fund votes
2025-06-17Meeting date

Proxy season: 2023-2024 2024-2025

Explore ZENTALIS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by ZENTALIS PHARMACEUTICALS INC.

These tallies are ZENTALIS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-18 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ZENTALIS PHARMACEUTICALS INC. — official shareholder meeting results, meeting held 2025-06-17
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Scott Myers	43,014,172	--	--	3,948,491	11,249,440	Majority: yes
Elect Director: Karan Takhar	30,655,734	--	--	16,306,929	11,249,440	Majority: yes
Elect Director: Luke Walker, M.D.	36,599,420	--	--	10,363,243	11,249,440	Majority: yes
Item 2 — Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.	58,100,230	10,761	101,112	--	0	Majority: yes
Item 3 — Approval, on an advisory (non-binding) basis, the compensation of the Company's named executive officers.	29,474,720	17,374,784	113,159	--	11,249,440	Majority: yes

Source: ZENTALIS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2025-06-18 — read the filing on EDGAR.

How asset managers voted at the ZENTALIS PHARMACEUTICALS INC. 2024-2025 meeting

Each item below shows how the 126 asset managers that disclosed a ZENTALIS PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

63% Majority: yes · of votes cast

FOR 63%AGAINST 37%

FOR: 29,474,720AGAINST: 17,374,784

ZENTALIS PHARMACEUTICALS INC.’s own tally for this item (“Item 3 — Approval, on an advisory (non-binding) basis, the compensation of the Company's named executive officers.”): 29,474,720 for, 17,374,784 against, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,951,934 outstanding shares: 41% for, 24% against (65% of the company cast a for/against vote).

The 125 asset managers below cast 60% of the shares they voted on this item FOR (23,454,678 for, 15,532,544 against).

FOR 59%AGAINST 39%

FOR: 23,454,678 (59.3%)AGAINST: 15,532,544 (39.3%)ABSTAIN: 1,298 (0.0%)UNKNOWN: 565,435 (1.4%)NOT VOTED: 4,000 (0.0%)

Largest asset managers voting on “TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.” at ZENTALIS PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Matrix Capital Management Company, LP	13,959,973	0	For
Vanguard	3,268,478	6,927	For
BlackRock	18,511	3,182,460	Against
Opaleye Management Inc.	1,910,000	0	For
Fidelity	0	1,531,878	Against
Federated Hermes	0	1,488,716	Against
GEODE CAPITAL MANAGEMENT, LLC	0	1,335,969	Against
PRIMECAP MANAGEMENT CO/CA/	1,163,520	0	For
Charles Schwab	0	980,124	Against
TYBOURNE CAPITAL MANAGEMENT (HK) LTD	0	961,486	Against
DE Shaw	0	926,914	Against
PRIMECAP Odyssey Funds	861,400	0	For
State Street	691,328	4,678	For
Decheng Capital LLC	0	0	Unknown
Woodline Partners LP	523,519	0	For
Nuveen	0	507,527	Against
5AM Venture Management, LLC	490,000	0	For
TIAA	0	472,207	Against
Connor, Clark & Lunn Investment Management Ltd.	0	330,539	Against
AQR	0	315,008	Against
Renaissance	0	307,947	Against
Invesco	0	267,051	Against
Northern Trust	258,237	48	For
Two Sigma	0	244,645	Against
Equitable	0	202,308	Against

Showing the 25 largest of 125 asset managers. See all 125 in the interactive database.

2. Election of Class II Directors to serve until the 2028 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal: Karan Takhar

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

65% Majority: yes · of votes cast

FOR 65%WITHHELD 35%

FOR: 30,655,734WITHHELD: 16,306,929

ZENTALIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Karan Takhar”): 30,655,734 for, 16,306,929 withheld, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,951,934 outstanding shares: 43% for, 23% withheld (65% of the company cast a for/withheld vote).

The 45 asset managers below cast 100% of the shares they voted on this item FOR (5,820,650 for, 0 against).

FOR 60%ABSTAIN 40%

FOR: 5,820,650 (59.6%)ABSTAIN: 3,952,408 (40.4%)

Largest asset managers voting on “Election of Class II Directors to serve until the 2028 Annual Meeting of Stockholders, and until their respect” at ZENTALIS PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	3,222,705	0	For
BlackRock	1,430,819	0	For
Fidelity	0	1,352,554	Abstain
PRIMECAP Odyssey Funds	861,400	0	For
Federated Hermes	0	729,178	Abstain
Charles Schwab	0	490,062	Abstain
TIAA	0	472,207	Abstain
Equitable	92,770	109,538	Abstain
BRIDGEWAY FUNDS INC	0	152,300	Abstain
Invesco	0	123,843	Abstain
QUANTITATIVE MASTER SERIES LLC	95,310	0	For
Thrivent	0	68,827	Abstain
Nationwide	14,342	53,278	Abstain
ETF Series Solutions	0	67,401	Abstain
Goldman Sachs	0	52,534	Abstain
Lincoln Financial	40,700	6,070	For
ETFis Series Trust I	0	35,939	Abstain
Global X	0	34,506	Abstain
Pacific Life	30,426	0	For
AIG/SunAmerica	0	29,192	Abstain
Bridge Builder Trust	25,484	0	For
John Hancock	0	23,139	Abstain
Northern Trust	0	22,398	Abstain
Russell Investments	0	20,716	Abstain
Voya	0	17,282	Abstain

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

3. Election of Class II Directors to serve until the 2028 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal: Luke Walker, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

78% Majority: yes · of votes cast

FOR 78%WITHHELD 22%

FOR: 36,599,420WITHHELD: 10,363,243

ZENTALIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Luke Walker, M.D.”): 36,599,420 for, 10,363,243 withheld, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,951,934 outstanding shares: 50.9% for, 14% withheld (65% of the company cast a for/withheld vote).

The 45 asset managers below cast 100% of the shares they voted on this item FOR (8,440,734 for, 0 against).

FOR 86%14%

FOR: 8,440,734 (86.4%)ABSTAIN: 1,332,324 (13.6%)

Largest asset managers voting on “Election of Class II Directors to serve until the 2028 Annual Meeting of Stockholders, and until their respect” at ZENTALIS PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	3,222,705	0	For
BlackRock	1,430,819	0	For
Fidelity	1,183,377	169,177	For
PRIMECAP Odyssey Funds	861,400	0	For
Federated Hermes	729,178	0	For
Charles Schwab	490,062	0	For
TIAA	0	472,207	Abstain
Equitable	92,770	109,538	Abstain
BRIDGEWAY FUNDS INC	0	152,300	Abstain
Invesco	123,843	0	For
QUANTITATIVE MASTER SERIES LLC	95,310	0	For
Thrivent	0	68,827	Abstain
Nationwide	16,217	51,403	Abstain
ETF Series Solutions	0	67,401	Abstain
Goldman Sachs	0	52,534	Abstain
Lincoln Financial	40,700	6,070	For
ETFis Series Trust I	0	35,939	Abstain
Global X	34,506	0	For
Pacific Life	30,426	0	For
AIG/SunAmerica	0	29,192	Abstain
Bridge Builder Trust	25,484	0	For
John Hancock	0	23,139	Abstain
Northern Trust	22,398	0	For
Russell Investments	20,716	0	For
Voya	0	17,282	Abstain

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

4. Election of Class II Directors to serve until the 2028 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal: Scott Myers

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%

FOR: 43,014,172WITHHELD: 3,948,491

ZENTALIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Scott Myers”): 43,014,172 for, 3,948,491 withheld, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,951,934 outstanding shares: 60% for, 5% withheld (65% of the company cast a for/withheld vote).

The 45 asset managers below cast 100% of the shares they voted on this item FOR (8,317,009 for, 0 against).

FOR 85%ABSTAIN 15%

FOR: 8,317,009 (85.1%)ABSTAIN: 1,456,049 (14.9%)

Largest asset managers voting on “Election of Class II Directors to serve until the 2028 Annual Meeting of Stockholders, and until their respect” at ZENTALIS PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	3,222,705	0	For
BlackRock	1,430,819	0	For
Fidelity	1,183,377	169,177	For
PRIMECAP Odyssey Funds	861,400	0	For
Federated Hermes	0	729,178	Abstain
Charles Schwab	0	490,062	Abstain
TIAA	472,207	0	For
Equitable	202,308	0	For
BRIDGEWAY FUNDS INC	152,300	0	For
Invesco	123,843	0	For
QUANTITATIVE MASTER SERIES LLC	95,310	0	For
Thrivent	68,827	0	For
Nationwide	67,620	0	For
ETF Series Solutions	67,401	0	For
Goldman Sachs	0	52,534	Abstain
Lincoln Financial	40,700	6,070	For
ETFis Series Trust I	35,939	0	For
Global X	34,506	0	For
Pacific Life	30,426	0	For
AIG/SunAmerica	29,192	0	For
Bridge Builder Trust	25,484	0	For
John Hancock	23,139	0	For
Northern Trust	22,398	0	For
Russell Investments	20,716	0	For
Voya	17,282	0	For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

5. TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 58,100,230AGAINST: 10,761

ZENTALIS PHARMACEUTICALS INC.’s own tally for this item (“Item 2 — Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.”): 58,100,230 for, 10,761 against, per its Form 8-K filed 2025-06-18 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 71,951,934 outstanding shares: 81% for, 0.1% against (81% of the company cast a for/against vote).

The 45 asset managers below cast 100% of the shares they voted on this item FOR (9,771,760 for, 0 against).

FOR 99.9%

FOR: 9,771,760 (100.0%)ABSTAIN: 1,298 (0.0%)

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FI” at ZENTALIS PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Vote
Vanguard	3,222,705	For
BlackRock	1,430,819	For
Fidelity	1,352,554	For
PRIMECAP Odyssey Funds	861,400	For
Federated Hermes	729,178	For
Charles Schwab	490,062	For
TIAA	472,207	For
Equitable	202,308	For
BRIDGEWAY FUNDS INC	152,300	For
Invesco	123,843	For
QUANTITATIVE MASTER SERIES LLC	95,310	For
Thrivent	68,827	For
Nationwide	67,620	For
ETF Series Solutions	67,401	For
Goldman Sachs	52,534	For
Lincoln Financial	46,770	For
ETFis Series Trust I	35,939	For
Global X	34,506	For
Pacific Life	30,426	For
AIG/SunAmerica	29,192	For
Bridge Builder Trust	25,484	For
John Hancock	23,139	For
Northern Trust	22,398	For
Russell Investments	20,716	For
Voya	17,282	For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Largest ZENTALIS PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked by the number of ZENTALIS PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 71,951,934 shares outstanding at the time of that meeting.

Top ZENTALIS PHARMACEUTICALS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	Matrix Capital Management Company, LP	19.40%
2	Vanguard	4.55%
3	BlackRock	4.45%
4	Opaleye Management Inc.	2.65%
5	Fidelity	2.13%
6	Federated Hermes	2.07%
7	GEODE CAPITAL MANAGEMENT, LLC	1.86%
8	PRIMECAP MANAGEMENT CO/CA/	1.62%
9	Charles Schwab	1.37%
10	TYBOURNE CAPITAL MANAGEMENT (HK) LTD	1.34%

Reported ZENTALIS PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

ZENTALIS PHARMACEUTICALS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Matrix Capital Management Master Fund, LP	19.40%	DEF14A
WALTERS GROUP	18.78%	13G
William T. Walters	9.80%	DEF14A
Andrew J. Schwab	6.72%	13G
Eventide Asset Management, LLC	6.22%	DEF14A
BlackRock	5.88%	13F
Barclays PLC	5.34%	13G
Squadron Master Fund LP	5.11%	13G
Vanguard Group	4.53%	13F
Millennium Management	4.27%	13F

Percentages above are of 71,951,934 shares outstanding, as reported by ZENTALIS PHARMACEUTICALS INC. on its Form 10-Q dated 2025-05-12 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ZENTALIS PHARMACEUTICALS INC.’s 10-Q dated 2025-05-12. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At ZENTALIS PHARMACEUTICALS INC.'s shareholder meeting held 2025-06-17, in the 2024-2025 proxy season, 126 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 731 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE… — FOR was 63% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ZENTALIS PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-18.

ZENTALIS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page).